- Home
- HTH vs BLTE Comparison
HTH vs BLTE Comparison
Compare HTH & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- BLTE
- Stock Information
- Founded
- HTH 1998
- BLTE 2018
- Country
- HTH United States
- BLTE United States
- Employees
- HTH N/A
- BLTE N/A
- Industry
- HTH Major Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- HTH Finance
- BLTE Health Care
- Exchange
- HTH Nasdaq
- BLTE Nasdaq
- Market Cap
- HTH 1.9B
- BLTE 1.9B
- IPO Year
- HTH 2004
- BLTE 2022
- Fundamental
- Price
- HTH $30.25
- BLTE $61.10
- Analyst Decision
- HTH Hold
- BLTE Strong Buy
- Analyst Count
- HTH 2
- BLTE 4
- Target Price
- HTH $33.00
- BLTE $96.67
- AVG Volume (30 Days)
- HTH 338.1K
- BLTE 29.7K
- Earning Date
- HTH 04-24-2025
- BLTE 05-14-2025
- Dividend Yield
- HTH 2.38%
- BLTE N/A
- EPS Growth
- HTH 15.07
- BLTE N/A
- EPS
- HTH 1.97
- BLTE N/A
- Revenue
- HTH $1,208,822,000.00
- BLTE N/A
- Revenue This Year
- HTH N/A
- BLTE N/A
- Revenue Next Year
- HTH $3.14
- BLTE N/A
- P/E Ratio
- HTH $15.37
- BLTE N/A
- Revenue Growth
- HTH 2.13
- BLTE N/A
- 52 Week Low
- HTH $26.67
- BLTE $40.00
- 52 Week High
- HTH $35.32
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- HTH 59.19
- BLTE 51.45
- Support Level
- HTH $29.53
- BLTE $59.04
- Resistance Level
- HTH $30.53
- BLTE $62.55
- Average True Range (ATR)
- HTH 0.76
- BLTE 2.51
- MACD
- HTH 0.20
- BLTE 0.32
- Stochastic Oscillator
- HTH 84.18
- BLTE 74.06
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.